The temporal divergence rate between phage tail-fibre protein diversity and bacterial surface receptor protein evolution — measurable from longitudinal WHO GLASS genomic surveillance metadata — predicts windows of maximum phage susceptibility in hospital-endemic strains, occurring when bacterial receptor evolution lags phage adaptation. A dynamic scheduling algorithm for phage therapy deployment that identifies and targets these susceptibility windows from real-time GLASS data will extend the therapeutic lifetime of phage preparations by ≥3× compared to fixed-dose protocols, demonstrable in A. baumannii and K. pneumoniae cohort data where GLASS provides longitudinal genomic resolution.

BiologyApr 22, 2026Evaluation Score: 70%

Adversarial Debate Score

55% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Grok: The hypothesis is falsifiable and leverages WHO GLASS data for real-time application, which is supported by papers on machine learning and surveillance data. However, it assumes a consistent lag in bacterial receptor evolution that may not hold across diverse strains, and counterarguments exist r...

ChatGPT: The hypothesis is innovative, falsifiable, and theoretically grounded in evolutionary trade-offs and surveillance data, but it overextends the current evidence: while some cited papers support phage-bacteria coevolution and real-time surveillance, direct proof that temporal divergence rates can p...

Mistral: The hypothesis is falsifiable and aligns with evolutionary trade-offs in phage-bacteria dynamics, but its reliance on GLASS data’s granularity and the assumption of predictable lag times introduces uncertainty. Counterarguments include ecological noise and bacterial compensatory evolution undermi...

Claude: The hypothesis conflates phenotypic AMR surveillance metadata from WHO GLASS (which tracks antibiotic resistance rates, not phage receptor genomics or tail-fibre protein sequences) with the granular longitudinal phage-host co-evolutionary data it would actually require, making the core measuremen...

Supporting Research Papers

The evolutionary trade-offs in phage-resistant Klebsiella pneumoniae entail cross-phage sensitization and loss of multidrug resistance.
Bacteriophage therapy is currently being evaluated as a critical complement to traditional antibiotic treatment. However, the emergence of phage resistance is perceived as a major hurdle to the sustai...
Pseudolysogeny-mediated evolutionary trade-offs favor phage therapy by limiting antibiotic resistance and virulence in Cutibacterium acnes
Phage therapy has mostly focused on strictly lytic phages, yet the ecological and evolutionary implications of pseudolysogeny remain poorly understood. Pseudolysogeny—where a phage genome persists in ...
Trade-offs between phage resistance and conjugative ability shape the ecological and evolutionary response of a multidrug resistance plasmid to plasmid-dependent phage
Forecasting Antimicrobial Resistance Trends Using Machine Learning on WHO GLASS Surveillance Data: A Retrieval-Augmented Generation Approach for Policy Decision Support
Antimicrobial resistance (AMR) is a growing global crisis projected to cause 10 million deaths per year by 2050. While the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) provi...

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

In hospital-endemic populations of A. baumannii and K. pneumoniae undergoing longitudinal genomic surveillance, there exists a computable metric D(t) = [rate of phage tail-fibre protein sequence diversification] − [rate of bacterial surface receptor protein sequence diversification], measured over sliding windows (e.g., 2–8 weeks) from serially collected isolate/phage genomes. The hypothesis claims: (a) periods where D(t) exceeds a learnable threshold θ (phage diversifying faster than receptor) are causally associated with elevated in-vitro phage susceptibility (measured by efficiency of plating, EOP ≥0.1, or time-kill AUC reduction ≥50% vs. control) in contemporaneously sampled bacterial isolates; and (b) a scheduling algorithm that times phage cocktail deployment to coincide with detected D(t) > θ windows will achieve ≥3× longer duration of maintained susceptibility (time-to-resistance-emergence) compared to fixed-interval/fixed-dose deployment, in matched retrospective or prospective cohorts. This is falsifiable via retrospective reconstruction on existing longitudinal isolate collections and prospective A/B cohort comparison.

Disproof criteria:

If D(t) shows no statistically significant association (Spearman/partial correlation, controlling for MIC and clonal lineage) with measured EOP/susceptibility across ≥3 independent hospital cohorts.
If dynamically-scheduled phage deployment fails to exceed fixed-protocol resistance-free duration by a pre-registered margin (<1.5× rather than ≥3×) in a matched prospective or in-vitro chemostat/co-culture evolution trial.
If receptor-evolution lag windows predicted from sequence data do not replicate in independent held-out cohorts (cross-validation AUC <0.65 for classifying "susceptibility window" vs "resistant window").
If confounders (clonal replacement, CRISPR spacer acquisition, MDR plasmid-linked fitness costs) explain the majority of variance in a multivariate model, reducing D(t)'s independent contribution to non-significance (partial R² <0.05).

EXPERIMENTAL_PROTOCOL (Minimum Viable Test): Phase 0 (in-silico feasibility, no new wet lab): Using existing public longitudinal genomic datasets (e.g., outbreak collections with serial isolates — CDC/Pathogen surveillance archives, published A. baumannii/K. pneumoniae outbreak WGS datasets, and any co-sequenced phage isolates from phage bank studies), compute D(t) retrospectively and test correlation with reported phage susceptibility phenotypes (EOP, host range panels) where available. Phase 1 (in-vitro validation): Chemostat/Morbidostat co-evolution experiment — coculture A. baumannii/K. pneumoniae clinical isolates with a diversifying phage cocktail over 60–90 days, serially sequencing both host and phage every 3–4 days; compute real D(t) in real time; test whether algorithm-triggered phage dosing (vs. fixed daily dosing) extends time-to-resistance. Phase 2 (retrospective clinical cohort, if Phase 0/1 succeed): Partner with a hospital ICU/ID unit with existing biobanked serial isolates + treatment records for compassionate-use phage therapy cases; reconstruct D(t) retrospectively and test correlation with observed clinical treatment durability.

Spine & Adversarial Read

highWHO GLASS does not currently collect phage genomic data or strain-resolved longitudinal sequencing at the frequency required (weekly) to compute meaningful divergence rates — the hypothesis's core data-source claim is not currently operationalizable, making 'demonstrable from GLASS data' a substantially overstated framing.
EVP acknowledges this in Boundary Conditions and restructures the protocol to use supplementary longitudinal WGS/phage-bank datasets rather than GLASS alone; however, this is a genuine unresolved gap — the discovery's title/claim should be narrowed to 'GLASS-compatible surveillance infrastructure' rather than GLASS as currently constituted, pending a formal GLASS data-access feasibility check.
highSequence-level divergence rate (dN/dS or substitution rate) in tail-fibre/receptor loci is a poor proxy for functional receptor-binding tropism shifts; synonymous mutations, recombination/horizontal gene transfer (common in tail-fibre modules via mosaicism), and epistatic interactions could decouple D(t) from actual susceptibility phenotype.
Protocol includes EOP phenotypic validation as ground truth rather than relying on sequence proxy alone, and multivariate models control for confounders; however, no explicit mosaicism/recombination-detection step (e.g., RDP4/GARD analysis) is built into the current methodology — this should be added as a required pre-processing step before dN/dS estimation, currently a methodological gap.
mediumWhy chemostat/morbidostat co-evolution as the validation method rather than, e.g., animal infection models or purely retrospective clinical data — the choice of in-vitro co-culture may not capture host-immune interactions that dominate real therapeutic outcomes, and the methodology justification for choosing this over alternatives is not explicitly argued.
Chemostat is justified implicitly by cost/scalability/replicate-count needs (n≥6 per arm, daily sampling over 90 days is infeasible in animal models at this budget), but the EVP does not explicitly argue why in-vitro results would generalize to clinical deployment before committing to Phase 2 — this justification gap should be closed by adding an intermediate murine/Galleria mellonella infection model validation step between Phase 1 and Phase 2 to bridge the in-vitro-to-clinical inference gap.

Experimental Protocol

Required datasets:

WHO GLASS metadata extracts (species, AMR phenotype, temporal/geographic metadata) — note: GLASS alone is insufficient; must be supplemented.
Longitudinal WGS isolate collections with serial sampling (e.g., NCBI Pathogen Detection, BV-BRC, published nosocomial outbreak genomic datasets for A. baumannii/K. pneumoniae).
Phage genome databases with tail-fibre/RBP annotations (INPHARED, Millard Lab phage genome database, GenBank phage RefSeq).
Paired phage-host phenotypic susceptibility data (EOP panels) — e.g., existing phage biobank host-range matrices (Eliava Institute-style datasets, published phage cocktail host-range studies).
In-house chemostat/morbidostat co-culture apparatus for Phase 1.
Compute environment: phylogenetic/molecular evolution toolchain (BEAST2, HyPhy dN/dS, IQ-TREE), bioinformatics pipeline (Snakemake/Nextflow), ML environment (Python/scikit-learn/XGBoost for threshold learning).

Success:

Phase 0: Statistically significant correlation (p<0.01, effect size r>0.4) between retrospective D(t) and susceptibility phenotype across ≥2 independent datasets.
Phase 1: Dynamic scheduling arm achieves ≥3× median time-to-resistance-emergence vs fixed-dosing arm (Cox HR ≤0.33, p<0.05), replicated across ≥2 bacterial species and ≥2 independent phage cocktails.
Cross-validated classification AUC ≥0.75 for predicting susceptibility windows from D(t) alone.
Effect replicates in ≥2 of 3 independent cohorts/experimental replicates.

Failure:

No significant correlation in Phase 0 (p>0.1) across available datasets — halt before Phase 1 investment.
Phase 1 shows <1.5× improvement or no significant hazard ratio difference.
D(t) threshold θ fails to generalize across sites (AUC <0.6 on held-out data).
Confounder-adjusted models show D(t) contributes <5% incremental variance explained.

ROI Projection

Commercial:

High-value dual output: (1) a diagnostic/decision-support software product (real-time genomic scheduling algorithm) licensable to phage therapy companies (e.g., Adaptive Phage Therapeutics, BiomX, Armata Pharmaceuticals) and hospital antimicrobial stewardship programs; (2) generates a reusable evolutionary-rate biomarker pipeline applicable beyond phage therapy to predicting antibiotic cycling windows. Estimated addressable market: phage therapy clinical services + AMR diagnostics decision-support, a growing niche within the ~$2B+ projected phage therapeutics market by early 2030s.

TIME_TO_RESULT_DAYS: 270

Implementation Sketch

# Phase 0: retrospective D(t) computation
for each cohort in longitudinal_datasets:
    phage_seqs, host_seqs = extract_serial_sequences(cohort)
    rbp_rate_t = compute_substitution_rate(phage_seqs, locus='tail_fibre', window=W)
    receptor_rate_t = compute_substitution_rate(host_seqs, locus='OMP/capsule', window=W)
    D_t = rbp_rate_t - receptor_rate_t
    susceptibility_t = measure_EOP(cohort, timepoints)
    correlation = mixed_effects_model(D_t, susceptibility_t,
                                       covariates=[clonal_lineage, AMR_genotype])
    log(cohort, correlation)

# Threshold learning
theta = cross_validate_threshold(D_t_all_cohorts, susceptibility_labels,
                                   model=XGBoostClassifier, folds=site_grouped_CV)

# Phase 1: dynamic scheduling algorithm
def scheduling_decision(D_t_current, theta, days_since_last_dose):
    if D_t_current > theta and days_since_last_dose > min_interval:
        return DEPLOY_PHAGE_COCKTAIL
    else:
        return HOLD

# Chemostat trial loop (per vessel, daily)
for day in range(90):
    sample_host_and_phage(vessel)
    D_t = update_Dt_estimate(vessel_history)
    if arm == 'dynamic':
        decision = scheduling_decision(D_t, theta, last_dose_day)
    else:
        decision = fixed_protocol(day)
    if decision == DEPLOY_PHAGE_COCKTAIL:
        administer_phage(vessel)
    resistance_status = plate_assay(vessel)  # EOP measurement
    log(vessel, day, D_t, resistance_status)

# Endpoint: Cox PH survival analysis on time-to-resistance across arms

Abort checkpoints:

Day 30: If fewer than 2 usable longitudinal paired datasets can be identified/curated, abort or pivot to prospective-only design.
Day 60 (Phase 0 complete): If correlation p>0.1 or r<0.2 across curated datasets, abort before committing to Phase 1 wet-lab costs.
Day 150 (Phase 1 interim, 50% of chemostat runs complete): If interim Cox HR shows no directional trend favoring dynamic arm (HR >0.7), abort remaining replicates.
Day 240: If threshold θ fails to cross-validate (AUC <0.6) on held-out chemostat vessel data, do not proceed to Phase 2 clinical cohort work.

NAMED_EXPERTS: []

CLOSEST_EXISTING_WORK: []

NOVELTY_NARROWING_REQUIRED: false

SPINE_STATEMENT: This hypothesis is testing whether the sign and magnitude of the divergence-rate differential between phage tail-fibre proteins and bacterial receptor proteins can predictively identify time-windows of maximal phage susceptibility, and whether scheduling phage deployment to these windows extends therapeutic efficacy at least threefold over fixed-dose protocols.

Source

AegisMind Research

Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started